New and interesting PROSTVAC data indicate broad therapeutic use in metastatic prostate cancer
Bavarian Nordic A/S presented further detailed PROSTVAC(TM) data at the European CanCer Organisation (ECCO), ECCO 15 - 34th ESMO Congress in Berlin, Germany. Further data from a Phase II double-blind, prospective randomized placebo-controlled study of 125 patients with metastatic prostate cancer was presented by Dr. Wayne Godfrey, Senior Medical Director, BN ImmunoTherapeutics.
The headline data as previously reported showed that patients in the PROSTVAC(TM) group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is 0.56 (95% CI 0.37-0.85). The statistical significance in the final data set is (p=0.006). PROSTVAC(TM) also demonstrated a very favourable safety and tolerability profile.
A new statistical analysis of the data set showed that patients receiving PROSTVAC(TM) benefitted from the treatment regardless of their general condition or their median predicted survival, determined by the Halabi score. Similarly, when grouped by a number of relevant parameters, e.g. PSA level, PROSTVAC(TM) patients benefitted from treatment as compared to the control group. This data indicates that PROSTVAC(TM) is universally applicable to a wide range of prostate cancer patients. This confirms PROSTVAC(TM)'s potential to address a significant medical need and market opportunity. Furthermore, it will be useful in further defining the patient population for the pivotal phase III program.
Other news from the department research and development
